Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABMG1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers
NEWS 25	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 26	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 27	APR 28	CAS patent authority coverage expanded
NEWS 28	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced

```
 NEWS 29  APR 28  Limits doubled for structure searching in CAS
                  REGISTRY

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:14:05 ON 29 APR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 06:14:27 ON 29 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 APR 2009  HIGHEST RN 1140067-87-3
DICTIONARY FILE UPDATES:  27 APR 2009  HIGHEST RN 1140067-87-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10519118.str
```



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
ring nodes :
1 2 3 4 5 6
chain bonds :
1-14 2-21 3-15 4-16 5-7 6-13 7-8 7-10 7-11 8-9 8-17 8-18 9-19 9-20
10-12 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-21 7-10 8-9
exact bonds :
1-14 3-15 4-16 5-7 6-13 7-8 7-11 8-17 8-18 9-19 9-20 10-12 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s L1 fam sam
SAMPLE SEARCH INITIATED 06:15:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1276 TO ITERATE

100.0% PROCESSED     1276 ITERATIONS                                 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         23377 TO    27663
PROJECTED ANSWERS:                8 TO      329

L2             8 SEA FAM SAM L1

=> s L1 fam full
FULL SEARCH INITIATED 06:15:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    24952 TO ITERATE

100.0% PROCESSED    24952 ITERATIONS                                69 ANSWERS
SEARCH TIME: 00.00.01

L3            69 SEA FAM FUL L1

=> file cap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      73.81      74.03

FILE 'CAPLUS' ENTERED AT 06:15:38 ON 29 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 29 Apr 2009 VOL 150 ISS 18
FILE LAST UPDATED: 28 Apr 2009 (20090428/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s L3
L4        2269 L3

=> s L3/COS
          2269 L3
         39842 COS/RL
L5          10 L3/COS
                (L3 (L) COS/RL)

=> d L5 1-10 ibib abs hitstr
```

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:763639 CAPLUS
DOCUMENT NUMBER: 147:173626
TITLE: Pharmaceutical compositions containing N-(phosphonoalkyl)-amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070161543	A1	20070712	US 2007-621287	20070109
US 7429575	B2	20080930		
AU 2007204755	A1	20070719	AU 2007-204755	20070109
CA 2637027	A1	20070719	CA 2007-2637027	20070109
WO 2007082206	A2	20070719	WO 2007-US60273	20070109
WO 2007082206	A3	20071213		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,

MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1979366	A2	20081015	EP 2007-717264	20070109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080306025	A1	20081211	US 2008-194203	20080819
CN 101395164	A	20090325	CN 2007-80007801	20080904
PRIORITY APPLN. INFO.:			US 2006-757614P	P 20060110
			US 2007-621287	A3 20070109
			WO 2007-US60273	W 20070109

OTHER SOURCE(S): MARPAT 147:173626

AB The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)glycine or N,N-bis(phosphonomethyl)glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system. N-(phosphonomethyl)creatinine and propylene glycol were used in the preparation of a topical composition

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing N-(phosphonoalkyl)-amino acids)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2007:146724 CAPLUS
DOCUMENT NUMBER:	146:235482
TITLE:	Topical deodorant compositions based on hydroxycitric acid
INVENTOR(S):	Gupta, Shyam K.
PATENT ASSIGNEE(S):	Bioderm Research, USA
SOURCE:	U.S. Pat. Appl. Publ., 6pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070031526	A1	20070208	US 2005-161511	20050805

PRIORITY APPLN. INFO.: US 2005-161511 20050805

AB This invention relates to the use of hydroxycitric acid and its derivs. in cosmetic and pharmaceutical compns. for reducing body malodor. Thus, a composition contained stearalkonium bentonite 0.5, aluminum chlorohydrate 7.0, niacinamide hydroxystearate 1.0, C12-15 alkyl benzoate 3.0, cyclopentasiloxane 6.5, tri-Et citrate 1.0, iso-Pr palmitate 1.0, and isobutane 80.0%.

IT 923587-25-1
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(topical deodorant compns. based on hydroxycitric acid)

RN 923587-25-1 CAPLUS

CN D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, compd. with α-(aminomethyl)-4-hydroxybenzenemethanol (1:?) (CA INDEX NAME)

CM 1

CRN 27750-10-3
CMF C6 H8 O8

Absolute stereochemistry. Rotation (-).



CM 2

CRN 104-14-3
CMF C8 H11 N O2



L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:491792 CAPLUS
DOCUMENT NUMBER: 145:14124
TITLE: Topical delivery system comprising esters of hydroxy acids for cosmetic and pharmaceutical agents
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): Bioderm Research, USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060110415	A1	20060525	US 2004-904665	20041122
US 20070166255	A1	20070719	US 2007-670942	20070202
PRIORITY APPLN. INFO.:			US 2004-904665 A2	20041122
			US 2005-161856 A2	20050819

AB This invention relates to topical compns. containing esters of hydroxy acids and their application in the deep-penetration delivery of beneficial cosmetic and pharmaceutical agents. An ester of a hydroxy acid is selected from alkyl and aryl esters of glycolic, malic, lactic, mandelic, ascorbic, phytic, salicylic, aleuritic, and tartaric acids, etc. Thus, a skin whitening serum was prepared containing Et lactate 20.0, hydroxypropyl guar 0.5,, quinacetophenone 5.0, PEG-6 70.0, arbutin 4.0, and preservatives 0.5 parts, resp. The product had a clear to slightly hazy serum-like appearance. It was absorbed rapidly with a silky smooth skin feel. Also, an arthritis pain relief anti-inflammatory gel was prepared containing tri-Et citrate 55.65, Polyamide-3 5.0, preservative 0.5, Boswellia serrata extract 0.05, N-acetylglucosamine 2.0, methylsulfonylmethane 5.0, Aloe vera 0.1, vitamin E 0.5, paeonol 0.5, magnolol 0.2, chondroitin sulfate 0.5, and zeolite 30.0 parts, resp.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical delivery systems comprising esters of hydroxy acids as penetration enhancers for cosmetic and pharmaceutical uses)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:98865 CAPLUS
DOCUMENT NUMBER: 142:162689
TITLE: Weight control compositions and methods for fat loss and lean body mass maintenance
INVENTOR(S): Boldt, Matthias
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050025844	A1	20050203	US 2003-633233	20030802
PRIORITY APPLN. INFO.:			US 2003-633233	20030802

AB The present invention provides compns. and methods that assist in

providing weight control. Compns. comprise caffeine, an adrenergic amine (e.g. synephrine, hordenine, octopamine, tyramine and N-methyltyramine,) forskolin, Guggulsterones, an α-2 receptor antagonist (e.g. yohimbine) and a vinca alkaloid (e.g. vinpocetine). Black pepper extract may be added as well in various alternative embodiments. Methods utilizing administration of nutrient compns. are disclosed as well.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(weight control compns. and methods for fat loss and lean body mass maintenance)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:995650 CAPLUS

DOCUMENT NUMBER: 141:416008

TITLE: Ion-pair delivery system for cosmetic and pharmaceutical compositions

INVENTOR(S): Gupta, Shyam K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 17

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040228884	A1	20041118	US 2003-439349	20030515
US 20060147508	A1	20060706	US 2006-307729	20060218
US 20070092461	A1	20070426	US 2006-309441	20060806
PRIORITY APPLN. INFO.:			US 2002-265000	A2 20021004
			US 2002-280519	A2 20021025
			US 2002-290933	A2 20021107
			US 2003-394851	A2 20030322
			US 2003-439349	A2 20030515
			US 2006-307729	A2 20060218

AB This invention relates to a novel ion-pair delivery system useful for cosmetic, pharmaceutical, and topical nutraceutical applications in which the functional performance and consumer aesthetics of an electron donor composition and an electron acceptor composition, or a proton donor composition and a proton acceptor composition, are synergistically enhanced when such compns. are combined in an ion-pair mode. During ion-pair bonding process, the electron donor composition or the proton acceptor composition become pos. charged and the electron acceptor composition or proton donor composition become neg. charged and thus bind together in an ionic manner. Such ion-pair compns. release their electronically bound components in their original state when such compns. are absorbed into skin and reach physiol. pH conditions.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ion-pair delivery system for cosmetic and pharmaceutical compns.)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:934139 CAPLUS
DOCUMENT NUMBER: 141:400499
TITLE: Cosmetic and pharmaceutical ion-pair delivery system based masks comprising biopolymer based films cross-linked with metal cations
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040219124	A1	20041104	US 2003-249701	20030501
US 20060198805	A1	20060907	US 2005-164709	20051202
PRIORITY APPLN. INFO.:			US 2003-249701	A2 20030501

AB The present invention discloses a novel ion-pair delivery system based mask compns. for face, hair, skin, and body applications. These compns. come off from the site of their application essentially in one piece with the appearance, for example, of a piece of sea-weed or a continuous film. These mask compns. are suitable for a variety of delivery system methods, such as peel-off mask, moisturizing mask, exfoliating mask, prosthetic mask, soaking mask, depilatory mask, rub-off mask, two-phase mask, two-compartment mask, heat-releasing mask, and such. These mask compns. are made from the biopolymer based films that are cross-linked with divalent or trivalent metal cations. During the crosslinking process, such divalent and trivalent metal cations may also act as release agents for other face, hair, skin, and body beneficial compns. in their enhanced bioavailable forms by an ion-pair activation mechanism.
IT 104-14-3, Octopamine
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic and pharmaceutical ion-pair delivery system based masks comprising biopolymer based films cross-linked with metal cations)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:877940 CAPLUS
DOCUMENT NUMBER: 141:370229
TITLE: Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040208902	A1	20041021	US 2003-418495	20030418
US 20060127430	A1	20060615	US 2006-307824	20060224
US 20070166339	A1	20070719	US 2007-684702	20070312
US 20070237834	A1	20071011	US 2007-760466	20070608
PRIORITY APPLN. INFO.:			US 2003-418495	A2 20030418
			US 2003-605191	A2 20030914
			US 2004-710011	A2 20040611
			US 2006-307824	A2 20060224

AB The present invention discloses the utilization of zeolites for controlled-release of cosmetic and pharmaceutical compns. by nano-diffusion technol. The treatment and protection of skin surface requires that certain compns. be delivered to the skin surface and allowed to remain on the skin surface for as long as possible before such ingredients are absorbed into deeper layers of skin and carried into the bloodstream. Zeolites do not absorb into the skin, which is useful for topical delivery of cosmetic and pharmaceutical compns., for example antiaging, anti-wrinkle, antioxidants, skin whitening, acne treatment, rosacea treatment, sun screens, UV blocks, anesthetics, skin soothers, anti-irritants, anti-inflammatory agents, vitamins, hormones, and such that are electronically attached to the outer surfaces of such zeolites and are released to the outer surface of skin by a diffusion-controlled thermodn. process. An anhydrous face mask controlled-release antiaging composition with heat-releasing effect. comprises magnesium sulfate (anhydrous) 30.0, glycerin 49.0, sodium potassium aluminosilicate (Zeolite A3) 20.0, an antiaging composition (an equal weight mixture of tetrahydrocurcumin, niacinamide lactate, copper ATP complex, glutathione, and carnosine)1.0%.
IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compns.)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:681187 CAPLUS
DOCUMENT NUMBER: 141:194959
TITLE: Skin firming anti-aging cosmetic compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040161435	A1	20040819	US 2003-248753	20030214

PRIORITY APPLN. INFO.: US 2003-248753 20030214

AB Cosmetic mask compns. suitable for face, neck, chin or body applications are disclosed. These compns. synergistically combine at least 1 skin beneficial cosmetic or pharmaceutical composition with at least one composition to promote excess fat reduction, cellulite control, or muscle toning benefits. The mask composition also contains at least one binder composition that binds with other beneficial ingredients by electrostatic, atomic, or ionic charges to synergistically enhance their topical site-specific benefits. These mask compns. are suitable for a variety of delivery system methods that include, e.g., peel-off mask, leave-in mask, moisturizing mask, and exfoliating mask. Thua, a facial mask composition contained chitosan 5.0, lactic acid 5.0, glycerin 18.0, water 65.8, hydroxycitric acid 5.0, niacinamide 0.5, glutathione, and preservatives 0.5%.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(skin firming anti-aging cosmetic compns.)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:609740 CAPLUS
DOCUMENT NUMBER: 141:162091
TITLE: Topical nutraceutical compositions with selective body slimming and tone firming antiaging benefits

INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146539	A1	20040729	US 2003-248508	20030124

PRIORITY APPLN. INFO.: US 2003-248508 20030124

AB Cosmetic or topical pharmaceutical compns. are described for external body part or organ slimming, firming, cellulite reduction, fat-reduction, and obesity control benefits that are in synergistic combination with benefits for the treatment of skin aging, skin wrinkles reduction, skin exfoliating, treatment of acne, treatment of rosacea, age-spots reduction, skin surface whitening, skin surface brightening striae distensae (stretch marks) reduction, treatment of pimples, treatment of skin infections and lesions, spider veins reduction, blood microcirculation (venous insufficiency) improvement, UVA/UVB protection of skin, and skin redness reduction These compns. thus provide multiple combinations of skin and external body part or organ enhancement benefits that can be selective and specific for external body parts and organs such as face, chin, cheeks, arms, "love handles" in abdomen area, eye lids and eye zone, neck, breasts, thighs, and hips. For example, a chitosan facial mask composition for the reduction of wrinkles and excess fat on cheeks and eyelids contained chitosan 5%, lactic acid 5%, glycerin 18%, water 65.8%, hydroxycitric acid 5%, niacinamide 0.5%, glutathione 0.2%, and preservatives 0.5%. First three components were mixed into a paste, other components were mixed sep. into a clear solution, and the paste and the solution were combined to obtain a clear gel product. The gel is applied on the face and neck and left for 10 to 30 min, then rinsed off.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(topical nutraceutical compns. with selective body slimming and tone firming antiaging benefits)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:20643 CAPLUS
DOCUMENT NUMBER: 140:77297
TITLE: Method for preparing cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and use thereof
INVENTOR(S): Lintner, Karl
PATENT ASSIGNEE(S): Sederma, Fr.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002941	A1	20040108	WO 2003-FR1950	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2841550	A1	20040102	FR 2002-7965	20020626
FR 2841550	B1	20070504		
AU 2003253080	A1	20040119	AU 2003-253080	20030625
EP 1532102	A1	20050525	EP 2003-761635	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060110343	A1	20060525	US 2005-519118	20050929
JP 2007106697	A	20070426	JP 2005-299255	20051013
KR 2007041310	A	20070418	KR 2006-71964	20060731
CN 101182299	A	20080521	CN 2007-10129837	20070727

PRIORITY APPLN. INFO.:

FR 2002-7965	A	20020626
WO 2003-FR1950	W	20030625
JP 2005-299255	A	20051013
KR 2006-71964	A	20060731

OTHER SOURCE(S): CASREACT 140:77297; MARPAT 140:77297

GI



I

AB The invention concerns cosmetic or dermopharmaceutical compns. comprising tyramine derivs. I [X = NR3R4, N:CR5R6; R1, R2 = H, halogen, alkyl, aryl, aralkyl, acyl, OH, alkoxy; R3, R4 = H, alkyl, aryl, aralkyl, acyl, sulfonyl, sugar; R5, R6 = H, alkyl, aryl, aralkyl; with the exception of tyramine itself, its OH derivs., its NH2 acyl derivs. {(un)branched, (un)saturated C1-24-acyl, C1-24-hydroxyacyl, C1-24-mercaptoacyl} and synephrine (I; X = NHMe, R1 = OH, R2 = H)], their optical isomers, isomeric mixts. and their cosmetically acceptable salts. Thus, N,N'-bis(tyramine)urea [I; X=NC(:O)NH(CH2)2C6H4OH-4 (II)] was prepared from tyramine hydrochloride and carbonyl diimidazole in THF containing K2CO3. The invention also concerns the method for preparing same and use thereof for reducing pigmentation. A formulation for a depigmentation cream using II is described.

IT 104-14-3DP, Octopamine, and salts
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(method for preparing cosmetic or dermopharmaceutical compns. comprising tyramine derivs. and use thereof)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s L3/THU
          2269 L3
       1119237 THU/RL
L6           75 L3/THU
                 (L3 (L) THU/RL)

=> s dermal OR skin
         18906 DERMAL
        300247 SKIN
         11592 SKINS
        306697 SKIN
                 (SKIN OR SKINS)
L7      312976 DERMAL OR SKIN

=> s L3 AND L7
          2269 L3
L8          26 L3 AND L7

=> d L8 1-26 ibib abs hitstr
```

L8 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1448307 CAPLUS
DOCUMENT NUMBER: 150:766
TITLE: Compositions comprising a phosphodiesterase-5 inhibitor and other agents, and their use in methods of treatment
INVENTOR(S): Held, Jerry M.
PATENT ASSIGNEE(S): Vivus, Inc., USA
SOURCE: PCT Int. Appl., 65pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008144061	A2	20081127	WO 2008-US6467	20080519
WO 2008144061	A3	20090212		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-930673P P 20070518
US 2007-962094P P 20070727

AB The invention discloses pharmaceutical compns. and methods for the treatment of various conditions, disorders, and diseases (e.g. neurodegenerative diseases or skin damage), and more particularly the treatment of such conditions, disorders, and diseases using therapeutic agents that include a phosphodiesterase-5 inhibitor in combination with one or more agents.

IT 104-14-3, Octopamine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. using phosphodiesterase 5 inhibitor and other agents, and therapeutic use)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:993749 CAPLUS
DOCUMENT NUMBER: 147:330433
TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling
PATENT ASSIGNEE(S): Tristrata, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228
WO 2007103687	A2	20070913	WO 2007-US62975	20070228
WO 2007103687	A3	20081211		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,

TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1998788 A2 20081210 EP 2007-757636 20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: US 2006-778128P P 20060301
WO 2007-US62975 W 20070228

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

IT 104-14-3, Octopamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for topical treatment of tar-responsive dermatol. disorders)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:763639 CAPLUS
DOCUMENT NUMBER: 147:173626
TITLE: Pharmaceutical compositions containing N-(phosphonoalkyl)-amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070161543	A1	20070712	US 2007-621287	20070109

US 7429575 B2 20080930
AU 2007204755 A1 20070719 AU 2007-204755 20070109
CA 2637027 A1 20070719 CA 2007-2637027 20070109
WO 2007082206 A2 20070719 WO 2007-US60273 20070109
WO 2007082206 A3 20071213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1979366 A2 20081015 EP 2007-717264 20070109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
US 20080306025 A1 20081211 US 2008-194203 20080819
CN 101395164 A 20090325 CN 2007-80007801 20080904
PRIORITY APPLN. INFO.: US 2006-757614P P 20060110
US 2007-621287 A3 20070109
WO 2007-US60273 W 20070109
OTHER SOURCE(S): MARPAT 147:173626

AB The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)glycine or N,N-bis(phosphonomethyl)glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system. N-(phosphonomethyl)creatinine and propylene glycol were used in the preparation of a topical composition

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing N-(phosphonoalkyl)-amino acids)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 26 CAPLUS

ACCESSION NUMBER: 2007:146724 CAPLUS
DOCUMENT NUMBER: 146:235482
TITLE: Topical deodorant compositions based on hydroxycitric acid
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): Bioderm Research, USA
SOURCE: U.S. Pat. Appl. Publ., 6pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070031526	A1	20070208	US 2005-161511	20050805
PRIORITY APPLN. INFO.:			US 2005-161511	20050805

AB This invention relates to the use of hydroxycitric acid and its derivs. in cosmetic and pharmaceutical compns. for reducing body malodor. Thus, a composition contained stearalkonium bentonite 0.5, aluminum chlorohydrate 7.0, niacinamide hydroxystearate 1.0, C12-15 alkyl benzoate 3.0, cyclopentasiloxane 6.5, tri-Et citrate 1.0, iso-Pr palmitate 1.0, and isobutane 80.0%.

IT 923587-25-1
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(topical deodorant compns. based on hydroxycitric acid)

RN 923587-25-1 CAPLUS
CN D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, compd. with α-(aminomethyl)-4-hydroxybenzenemethanol (1:?) (CA INDEX NAME)

CM 1

CRN 27750-10-3
CMF C6 H8 O8

Absolute stereochemistry. Rotation (-).



CM 2

CRN 104-14-3
CMF C8 H11 N O2



L8 ANSWER 5 OF 26 CAPLUS

ACCESSION NUMBER: 2006:1342373 CAPLUS
DOCUMENT NUMBER: 146:77532
TITLE: Methods and kits for obtaining a metabolic profile of living animal or plant cells in a multi-test format
INVENTOR(S): Bochner, Barry; Wiater, Larry
PATENT ASSIGNEE(S): Biolog Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 67pp., Cont.-in-part of U.S. Ser. No. 192,161.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060286627	A1	20061221	US 2006-418804	20060505
US 20030162164	A1	20030828	US 2002-126345	20020419
WO 2003089652	A2	20031030	WO 2003-US11866	20030416
WO 2003089652	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003223660	A1	20031103	AU 2003-223660	20030416
EP 1501938	A2	20050202	EP 2003-719801	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050260558	A1	20051124	US 2005-192161	20050727

PRIORITY APPLN. INFO.:		
US 2001-285541P	P	20010420
US 2002-126345	B1	20020419
US 2005-678566P	P	20050505
US 2005-192161	A2	20050727
WO 2003-US11866	W	20030416

AB The present invention relates to growing and testing eukaryotic cells (e.g., animal or plant cells) in a multi-test format. In particular, the present invention provides methods and kits for obtaining a complex metabolic profile of animal cells. In addition, the present invention provides tools for assaying the effects of candidate compds. (e.g., hormones) on substrate utilization by mammalian cells. A549 cells were suspended at 400,000 cells/mL in RPMI salts+RPMI-vitamins+1+ Pen/Strep (Penicillin/Streptomycin) without amino acids but containing either 5 % or 20 % dialyzed or non-dialyzed FCS. Cells were dispensed in 50 uL to wells containing a plurality of testing substrates (glycogen, glucose and pyruvate among others) at final concns. of 20, 15, 10.5, 2.5 and 1.2 mM of each testing substrate. The cells were incubated for 2 days at 37° under 5 % CO2-95 % air (preincubation phase), before a redox dye mix was added. The cells were incubated for an addnl. 5 h at 37° under 5 % CO2-95 % air (incubation phase), before color development was measured. A metabolic profile of A549 cells in the presence of serum was obtained.

IT 104-14-3, (±)-Octopamine
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(as testing substrate; kits and methods for obtaining metabolic profiles of living animal or plant cells)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:681023 CAPLUS
DOCUMENT NUMBER: 145:174286
TITLE: Pharmaceutical compositions comprising o-acetylsalicyl derivatives of amino saccharides and amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074114	A2	20060713	WO 2005-US47669	20060103
WO 2006074114	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20060166901	A1	20060727	US 2005-320530	20051229
AU 2006204136	A1	20060713	AU 2006-204136	20060103
CA 2593055	A1	20060713	CA 2006-2593055	20060103
EP 1843661	A2	20071017	EP 2005-856124	20060103
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008526774	T	20080724	JP 2007-549694	20060103
CN 101128117	A	20080220	CN 2005-80048674	20070824

PRIORITY APPLN. INFO.:

US 2005-640225P	P	20050103
US 2005-320530	A	20051229
WO 2005-US47669	W	20060103

AB The embodiments described herein include a composition and method of treatment using compns. that include at least 1 acetylsalicyl derivative The compns. and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems. N-(O-acetylsalicyl)-D-galactosamine 5 g was dissolved in warm propylene glycol 35 mL, and the solution thus obtained was mixed with hydrophilic ointment or oil-in-water cream (60 g). The cream thus prepared had pH 3.9 and contained 5% N-(O-acetylsalicyl)-D-galactosamine.

IT 104-14-3, Octopamine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising acetylsalicyl derivs. of amino saccharides and amino acids)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:491792 CAPLUS
DOCUMENT NUMBER: 145:14124
TITLE: Topical delivery system comprising esters of hydroxy acids for cosmetic and pharmaceutical agents
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): Bioderm Research, USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060110415	A1	20060525	US 2004-904665	20041122
US 20070166255	A1	20070719	US 2007-670942	20070202
PRIORITY APPLN. INFO.:			US 2004-904665 A2	20041122
			US 2005-161856 A2	20050819

AB This invention relates to topical compns. containing esters of hydroxy acids and their application in the deep-penetration delivery of beneficial cosmetic and pharmaceutical agents. An ester of a hydroxy acid is selected from alkyl and aryl esters of glycolic, malic, lactic, mandelic, ascorbic, phytic, salicylic, aleuritic, and tartaric acids, etc. Thus, a skin whitening serum was prepared containing Et lactate 20.0, hydroxypropyl guar 0.5,, quinacetophenone 5.0, PEG-6 70.0, arbutin 4.0, and preservatives 0.5 parts, resp. The product had a clear to slightly hazy serum-like appearance. It was absorbed rapidly with a silky smooth skin feel. Also, an arthritis pain relief anti-inflammatory gel was prepared containing tri-Et citrate 55.65, Polyamide-3 5.0, preservative 0.5, Boswellia serrata extract 0.05, N-acetylglucosamine 2.0, methylsulfonylmethane 5.0, Aloe vera 0.1, vitamin E 0.5, paeonol 0.5, magnolol 0.2, chondroitin sulfate 0.5, and zeolite 30.0 parts, resp.
IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical delivery systems comprising esters of hydroxy acids as penetration enhancers for cosmetic and pharmaceutical uses)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:995650 CAPLUS
DOCUMENT NUMBER: 141:416008
TITLE: Ion-pair delivery system for cosmetic and pharmaceutical compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040228884	A1	20041118	US 2003-439349	20030515
US 20060147508	A1	20060706	US 2006-307729	20060218
US 20070092461	A1	20070426	US 2006-309441	20060806
PRIORITY APPLN. INFO.:			US 2002-265000 A2	20021004
			US 2002-280519 A2	20021025
			US 2002-290933 A2	20021107
			US 2003-394851 A2	20030322
			US 2003-439349 A2	20030515
			US 2006-307729 A2	20060218

AB This invention relates to a novel ion-pair delivery system useful for cosmetic, pharmaceutical, and topical nutraceutical applications in which the functional performance and consumer aesthetics of an electron donor composition and an electron acceptor composition, or a proton donor composition and a proton acceptor composition, are synergistically enhanced when such compns. are combined in an ion-pair mode. During ion-pair bonding process, the electron donor composition or the proton acceptor composition become pos. charged and the electron acceptor composition or proton donor composition become neg. charged and thus bind together in an ionic manner. Such ion-pair compns. release their electronically bound components in their original state when such compns. are absorbed into skin and reach physiol. pH conditions.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ion-pair delivery system for cosmetic and pharmaceutical compns.)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:934139 CAPLUS
DOCUMENT NUMBER: 141:400499
TITLE: Cosmetic and pharmaceutical ion-pair delivery system based masks comprising biopolymer based films cross-linked with metal cations
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040219124	A1	20041104	US 2003-249701	20030501
US 20060198805	A1	20060907	US 2005-164709	20051202

PRIORITY APPLN. INFO.: US 2003-249701 A2 20030501

AB The present invention discloses a novel ion-pair delivery system based mask compns. for face, hair, skin, and body applications. These compns. come off from the site of their application essentially in one piece with the appearance, for example, of a piece of sea-weed or a continuous film. These mask compns. are suitable for a variety of delivery system methods, such as peel-off mask, moisturizing mask, exfoliating mask, prosthetic mask, soaking mask, depilatory mask, rub-off mask, two-phase mask, two-compartment mask, heat-releasing mask, and such. These mask compns. are made from the biopolymer based films that are cross-linked with divalent or trivalent metal cations. During the crosslinking process, such divalent and trivalent metal cations may also act as release agents for other face, hair, skin, and body beneficial compns. in their enhanced bioavailable forms by an ion-pair activation mechanism.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic and pharmaceutical ion-pair delivery system based masks comprising biopolymer based films cross-linked with metal cations)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:877940 CAPLUS
DOCUMENT NUMBER: 141:370229
TITLE: Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040208902	A1	20041021	US 2003-418495	20030418
US 20060127430	A1	20060615	US 2006-307824	20060224
US 20070166339	A1	20070719	US 2007-684702	20070312
US 20070237834	A1	20071011	US 2007-760466	20070608
PRIORITY APPLN. INFO.:			US 2003-418495	A2 20030418
			US 2003-605191	A2 20030914
			US 2004-710011	A2 20040611
			US 2006-307824	A2 20060224

AB The present invention discloses the utilization of zeolites for controlled-release of cosmetic and pharmaceutical compns. by nano-diffusion technol. The treatment and protection of skin surface requires that certain compns. be delivered to the skin surface and allowed to remain on the skin surface for as long as possible before such ingredients are absorbed into deeper layers of skin and carried into the bloodstream. Zeolites do not absorb into the skin, which is useful for topical delivery of cosmetic and pharmaceutical compns., for example antiaging, anti-wrinkle, antioxidants, skin whitening, acne treatment, rosacea treatment, sun screens, UV blocks, anesthetics, skin soothers, anti-irritants, anti-inflammatory agents, vitamins, hormones, and such that are electronically attached to the outer surfaces of such zeolites and are released to the outer surface of skin by a diffusion-controlled thermodn. process. An anhydrous face mask controlled-release antiaging composition with heat-releasing effect. comprises magnesium sulfate (anhydrous) 30.0, glycerin 49.0, sodium potassium aluminosilicate (Zeolite A3) 20.0, an antiaging composition (an equal weight mixture of tetrahydrocurcumin, niacinamide lactate, copper ATP complex, glutathione, and carnosine)1.0%.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compns.)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:780544 CAPLUS
DOCUMENT NUMBER: 141:301421
TITLE: Improved bioavailability and improved delivery of alkaline drugs
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080468	A1	20040923	WO 2004-US6699	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040214215	A1	20041028	US 2004-792273	20040304
AU 2004220597	A1	20040923	AU 2004-220597	20040305
CA 2517782	A1	20040923	CA 2004-2517782	20040305
EP 1601366	A1	20051207	EP 2004-717955	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-452557P P 20030307
US 2004-792273 A 20040304
WO 2004-US6699 A 20040305
OTHER SOURCE(S): MARPAT 141:301421
AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an alkaline pharmaceutical and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, diphenhydramine hydrochloride 29 g (0.1 mol) was dissolved in water (50 mL) and 5N sodium hydroxide (20 mL) was slowly added to generate diphenhydramine as a free base as shown by the formation of oily ppts. and the change from pH 5.5 to 9.4. Gluconolactone 18 g (0.1 mol) was added to form a mol. complex between the diphenhydramine free base and gluconic acid/gluconolactone as shown by the disappearance of the oily ppts. and the change from pH 9.4 to 7.4. The solution thus obtained contained 0.1 mol diphenhydramine in mol. complex with 0.1 mol gluconic acid/gluconolactone. This concentrated stock solution was used for various forms of topical formulations including oil-in-water creams, lotions, gels and solns.
IT 104-14-3, Octopamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved bioavailability and improved delivery of alkaline drugs using hydroxy acids)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:780130 CAPLUS
DOCUMENT NUMBER: 141:282441
TITLE: Hydroxycitric acid derivatives for body slimming and tone firming compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040185069	A1	20040923	US 2003-394851	20030322
US 20060147508	A1	20060706	US 2006-307729	20060218
PRIORITY APPLN. INFO.:			US 2002-265000 A2	20021004
			US 2002-280519 A2	20021025
			US 2002-290933 A2	20021107
			US 2003-394851 A2	20030322
			US 2003-439349 A2	20030515

AB The present invention discloses cosmetic or topical pharmaceutical compns. for body slimming, firming, cellulite reduction, fat-reduction, and obesity control benefits that can be selective and specific for external body parts and organs such as face, chin, cheeks, arms, "love handles" in abdomen area, eye lids and eye zone, neck, breasts, thighs, and hips. These compns. include a synergistic, bioavailability-enhanced ion-pair combination of Hydroxycitric acid or Hydroxycitric acid derivs. with certain organic bases such as Niacinamide, Niacin, Pyridoxine, Aminophylline, Caffeine, Carnitine, Creatine, Chitosan, Allantoin, Glucosamine, Phaseolamine, Chromium Picolinate, Theobromine, Theophylline, and such.
IT 757237-79-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxycitric acid derivs. for body slimming and tone firming compns.)
RN 757237-79-9 CAPLUS
CN Pentaric acid, 3-C-carboxy-2-deoxy-, compd. with α-(aminomethyl)-4-hydroxybenzenemethanol (9CI) (CA INDEX NAME)

CM 1

CRN 6205-14-7
CMF C6 H8 O8



CM 2

CRN 104-14-3
CMF C8 H11 N O2



L8 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:681187 CAPLUS
DOCUMENT NUMBER: 141:194959
TITLE: Skin firming anti-aging cosmetic compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040161435	A1	20040819	US 2003-248753	20030214
PRIORITY APPLN. INFO.:			US 2003-248753	20030214

AB Cosmetic mask compns. suitable for face, neck, chin or body applications are disclosed. These compns. synergistically combine at least 1 skin beneficial cosmetic or pharmaceutical composition with at least one composition to promote excess fat reduction, cellulite control, or muscle toning benefits. The mask composition also contains at least one binder composition that binds with other beneficial ingredients by electrostatic, atomic, or ionic charges to synergistically enhance their topical site-specific benefits. These mask compns. are suitable for a variety of delivery system methods that include, e.g., peel-off mask, leave-in mask, moisturizing mask, and exfoliating mask. Thua, a facial mask composition contained chitosan 5.0, lactic acid 5.0, glycerin 18.0, water 65.8, hydroxycitric acid 5.0, niacinamide 0.5, glutathione, and preservatives 0.5%.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(skin firming anti-aging cosmetic compns.)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:609740 CAPLUS
DOCUMENT NUMBER: 141:162091
TITLE: Topical nutraceutical compositions with selective body slimming and tone firming antiaging benefits
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146539	A1	20040729	US 2003-248508	20030124

PRIORITY APPLN. INFO.: US 2003-248508 20030124

AB Cosmetic or topical pharmaceutical compns. are described for external body part or organ slimming, firming, cellulite reduction, fat-reduction, and obesity control benefits that are in synergistic combination with benefits for the treatment of skin aging, skin wrinkles reduction, skin exfoliating, treatment of acne, treatment of rosacea, age-spots reduction, skin surface whitening, skin surface brightening striae distensae (stretch marks) reduction, treatment of pimples, treatment of skin infections and lesions, spider veins reduction, blood microcirculation (venous insufficiency) improvement, UVA/UVB protection of skin, and skin redness reduction These compns. thus provide multiple combinations of skin and external body part or organ enhancement benefits that can be selective and specific for external body parts and organs such as face, chin, cheeks, arms, "love handles" in abdomen area, eye lids and eye zone, neck, breasts, thighs, and hips. For example, a chitosan facial mask composition for the reduction of wrinkles and excess fat on cheeks and eyelids contained chitosan 5%, lactic acid 5%, glycerin 18%, water 65.8%, hydroxycitric acid 5%, niacinamide 0.5%, glutathione 0.2%, and preservatives 0.5%. First three components were mixed into a paste, other components were mixed sep. into a clear solution, and the paste and the solution were combined to obtain a clear gel product. The gel is applied on the face and neck and left for 10 to 30 min, then rinsed off.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(topical nutraceutical compns. with selective body slimming and tone firming antiaging benefits)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:20643 CAPLUS
DOCUMENT NUMBER: 140:77297
TITLE: Method for preparing cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and use thereof
INVENTOR(S): Lintner, Karl
PATENT ASSIGNEE(S): Sederma, Fr.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002941	A1	20040108	WO 2003-FR1950	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2841550	A1	20040102	FR 2002-7965	20020626
FR 2841550	B1	20070504		
AU 2003253080	A1	20040119	AU 2003-253080	20030625
EP 1532102	A1	20050525	EP 2003-761635	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060110343	A1	20060525	US 2005-519118	20050929
JP 2007106697	A	20070426	JP 2005-299255	20051013
KR 2007041310	A	20070418	KR 2006-71964	20060731
CN 101182299	A	20080521	CN 2007-10129837	20070727

PRIORITY APPLN. INFO.:			
	FR 2002-7965	A	20020626
	WO 2003-FR1950	W	20030625
	JP 2005-299255	A	20051013
	KR 2006-71964	A	20060731

OTHER SOURCE(S): CASREACT 140:77297; MARPAT 140:77297
GI



I

AB The invention concerns cosmetic or dermopharmaceutical compns. comprising tyramine derivs. I [X = NR3R4, N:CR5R6; R1, R2 = H, halogen, alkyl, aryl, aralkyl, acyl, OH, alkoxy; R3, R4 = H, alkyl, aryl, aralkyl, acyl, sulfonyl, sugar; R5, R6 = H, alkyl, aryl, aralkyl; with the exception of tyramine itself, its OH derivs., its NH2 acyl derivs. {(un)branched, (un)saturated C1-24-acyl, C1-24-hydroxyacyl, C1-24-mercaptoacyl} and synephrine (I; X = NHMe, R1 = OH, R2 = H)], their optical isomers, isomeric mixts. and their cosmetically acceptable salts. Thus, N,N'-bis(tyramine)urea [I; X=NC(:O)NH(CH2)2C6H4OH-4 (II)] was prepared from tyramine hydrochloride and carbonyl diimidazole in THF containing K2CO3. The invention also concerns the method for preparing same and use thereof for reducing pigmentation. A formulation for a depigmentation cream using II is described.

IT 104-14-3DP, Octopamine, and salts
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for preparing cosmetic or dermopharmaceutical compns. comprising tyramine derivs. and use thereof)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:206655 CAPLUS

DOCUMENT NUMBER: 132:231983

TITLE: Medicament combinations for therapy of erectile dysfunction

INVENTOR(S): Dunzendorfer, Udo; Will, Gottfried

PATENT ASSIGNEE(S): Germany

SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19844162	A1	20000330	DE 1998-19844162	19980925
EP 995441	A2	20000426	EP 1999-118622	19990921
EP 995441	A3	20001102		

EP 995441 B1 20020724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
AT 220909 T 20020815 AT 1999-118622 19990921
ES 2190160 T3 20030716 ES 1999-118622 19990921
PRIORITY APPLN. INFO.: DE 1998-19844162 A 19980925

AB Midodrine, etilefrine, oxilofrine, pholedrine, norfenefrine, ergotoxins and their dihydro derivs., α-sympathomimetics, and α-receptor antagonists are used in combination with sildenafil to elevate tissue levels of CAMP, cGMP, and NO and improve circulation in the corpora cavernosa. Alternatively, a combination of L-arginine ginsenoside, ginkgo, and midodrine may be used. Sildenafil may be conjugated to the other drug in the combination by an ester or amide bond, or the components of the combination may be incorporated into a 2-compartment, enteric-coated, or controlled-release formulation in the form of a skin cream, lotion, tablet, lozenge, or injection. Thus, sildenafil-resistant patients showed a good response to a combination of 50 mg sildenafil and 25 mg midodrine.

IT 104-14-3, Octopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sildenafil combined with; medicament combinations for therapy of erectile dysfunction)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:51324 CAPLUS
DOCUMENT NUMBER: 130:246870
TITLE: Transmitter release and uptake evoked by the amphibian skin alkaloid, pumiliotoxin-B (PTX-B), in the electrically stimulated mouse vas deferens preparation (MVD)
AUTHOR(S): Severini, C.; Erspamer, G. Falconieri; Erspamer, V.
CORPORATE SOURCE: Institute of Neurobiology, CNR, Rome, 001 37, Italy
SOURCE: Journal of Autonomic Pharmacology (1998), 18(6), 333-342
CODEN: JAPHDU; ISSN: 0144-1795
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Upon elec. stimulation three transmitters are known to be released from the adrenergic nerve terminals of the isolated MVD preparation: two motor transmitters (noradrenaline (NA) and ATP) acting synergistically to provoke twitch contraction, and an inhibitory transmitter, the peptide NPY. The frog alkaloid pumiliotoxin-B (PTX-B) displayed two opposite effects on the elec. stimulated MVD: at low concns. (0.1-0.3 μM) it caused twitch depression, at higher concns. (0.5-2 μM) there was a potent twitch stimulation. Transmitters and/or receptors involved in the depressive effect could not be clearly identified, although interference with NPY is possible. On the other hand, the potent twitch stimulation

caused by PTX-B may be due to exaggerated release of the same transmitters (NA and ATP) involved in twitch stimulation produced by elec. stimulation. Opening by PTX-B of the Na+ channels on the membrane of the adrenergic nerve terminals causes activation of the amine pump facilitating re-uptake of not only endogenous NA but also of exogenous catecholamines.

IT 104-14-3, Octopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(transmitter release and uptake evoked by pumiliotoxin-B in the elec. stimulated mouse vas deferens preparation)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:628528 CAPLUS
DOCUMENT NUMBER: 125:265996
ORIGINAL REFERENCE NO.: 125:49393a,49396a
TITLE: Treatment of herpes simplex infections with β-adrenergic antagonists or α-adrenergic agonists
INVENTOR(S): Gebhardt, Bryan M.; Kaufman, Herbert E.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9625163	A1	19960822	WO 1996-US2026	19960214

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1995-388574 A 19950214

AB Both herpes simplex viruses (HSV-1 and HSV-2) produce a variety of infections involving mucocutaneous surfaces, the central nervous system, and occasionally visceral organs. HSV is a neurotropic virus: following initial infection, the HSV may remain dormant for long periods of time within the cell bodies of neurons of the trigeminal ganglion. Periodically the virus reactivates, traveling down the branches of the trigeminal nerve to the ends, where it causes painful and unsightly skin lesions, or into the central nervous system or viscera, where it may produce debilitating or life-threatening tissue damage; administration of β-adrenergic antagonists, or α-adrenergic agonists, blocks reactivation of HSV, and thus can prevent recurrence of HSV infection. The efficacy of propanolol (I) in suppression of the incidence of viral reactivation following heat stress induction in mice was investigated. Fewer of the I-treated animals had infectious HSV in the precorneal tear film 24 h after induction of reactivation by

hyperthermia, compared with saline-treated control animals.

IT 104-14-3, Octopamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of herpes simplex infections with β-adrenergic antagonists or α-adrenergic agonists)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:234892 CAPLUS

DOCUMENT NUMBER: 124:311645

ORIGINAL REFERENCE NO.: 124:57635a,57638a

TITLE: A new method for double immunolabeling with primary antibodies from identical species

AUTHOR(S): Eichmueller, Stefan; Stevenson, Paul A.; Paus, Ralf

CORPORATE SOURCE: Department of Dermatology, Virchow-Hospital, Humboldt-Universitaet zu Berlin, Augustenburger Platz 1, 13344, Berlin, Germany

SOURCE: Journal of Immunological Methods (1996), 190(2), 255-65
CODEN: JIMMBG; ISSN: 0022-1759

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB There are several double immunolabeling methods but each has its drawbacks. More often than not, antibodies with the required specificities are available in only one species and their use normally produces false labels due to cross-reactivity. We describe a new and reliable technique for staining with primary antibodies from the same species, that can even be employed on tissues of the donor species. The protocol avoids cross-reactivities without loss in sensitivity, uses com. available reagents, and takes advantage of enzymic detection, although it can be adapted for fluorescent labeling. Briefly, tissue is incubated with one primary antibody, followed by a peroxidase-coupled secondary antibody which is detected by using aminoethylcarbazole to give a red reaction product. Meanwhile, the next primary antibody is coupled in vitro to a biotinylated secondary antibody and excess binding sites quenched with normal immune serum from the same species as the primary antibody. This complex is applied to tissue and detected by the avidin-biotin/alkaline phosphatase technique using naphthol-AS-MX-phosphate/Fast Blue BB to produce a blue label. In addition to extensive controls, the reliability and broad applicability of this method was confirmed in: (1) murine skin cryostat sections to covisualize antigen-presenting cells (MHC class II-immunoreactive '-ir') with either antigen detecting T lymphocytes (CD4-ir) or Langerhans cells (NLDC-145-ir) and (2) locust (Insecta) abdominal ganglion paraffin sections, where it is known that immunoreactivities for octopamine and a FMRFamide-related peptide are colocalized in only one, uniquely identifiable neuron.

IT 104-14-3, Octopamine

RL: ANT (Analyte); ANST (Analytical study)
(double immunolabeling with primary antibodies from identical species)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1989:29110 CAPLUS
DOCUMENT NUMBER: 110:29110
ORIGINAL REFERENCE NO.: 110:4810h,4811a
TITLE: Pharmaceuticals containing N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide for the treatment of circulation disorders
INVENTOR(S): Kitamura, Kenji; Fuji, Seishiro; Nishitani, Hiroshi; Ishiwatari, Katsumi
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63068551	A	19880328	JP 1986-213225	19860910

PRIORITY APPLN. INFO.: JP 1986-213225 19860910
OTHER SOURCE(S): CASREACT 110:29110
GI



I

AB The title benzamide derivative I is prepared and formulated. PhCOCl (7.4 g) was added to a solution of 10.0 g p-HOC6H4CH(OH)CH2NH2.HCl in pyridine with stirring to give 9.2 g I, which showed 19.3% decrease in systolic blood pressure at 100 mg/kg i.p. in rabbits. A 70% EtOH solution containing 0.1% I was applied to the scalp to show effective hair growth in a trichogram test. A capsule formulation containing I 100, microcryst. cellulose 100, and lactose 200 mg was prepared as antihypertensive medicine. A hair tonic lotion was formulated with 95% EtOH 80.0, I 0.1, castor oil-ethylene oxide adduct 0.5, distilled H2O 19.0 wt%, and suitable amount of color and fragrance. Addnl. formulations were given.
IT 770-05-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(benzoylation of)

RN 770-05-8 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

L8 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1988:555966 CAPLUS
DOCUMENT NUMBER: 109:155966
ORIGINAL REFERENCE NO.: 109:25825a,25828a
TITLE: Sunscreens containing N-(hydroxystyryl)benzamide
INVENTOR(S): Fujii, Seishiro; Nishitani, Hiroshi; Kitamura, Kanemoto; Ishiwatari, Katsumi
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62283912	A	19871209	JP 1986-127043	19860531

PRIORITY APPLN. INFO.: JP 1986-127043 19860531
GI



I

AB A sunscreen composition comprises N-(hydroxystyryl)benzamide (I) as a UV absorber. I absorbs wavelength 290-320 nm of sun rays and prevents inflammations. Octopamine-HCl dissolved in pyridine was reacted with benzoyl chloride to give N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide, which was refluxed in toluene in the presence of Al2O3 to give cis- and trans-N-(4-hydroxystyryl)benzamide. The above compds. had no skin -irritating side effects and no phototoxicity. A sunscreen cream contained water 41.0, polyethylene glycol 5.0, a dispersing agent q.s., cetyl alc. 5.0, vaseline 10.0, olive oil 15.0, liquid paraffin 5.0, microcryst. wax 5.0, glyceryl monostearate 2.0, polyoxyethylene sorbitan monostearate 2.0, N-(4-hydroxystyryl)benzamide 5.0% by weight, perfume q.s., preservative q.s., antioxidant q.s., TiO2 5.0% by weight, and color q.s.
IT 770-05-8, Octopamine hydrochloride
RL: BIOL (Biological study)
(condensation of, with benzoyl chloride)

RN 770-05-8 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy-, hydrochloride (1:1)
(CA INDEX NAME)



L8 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1986:578457 CAPLUS
DOCUMENT NUMBER: 105:178457
ORIGINAL REFERENCE NO.: 105:28675a,28678a
TITLE: Percutaneous absorption accelerator for ionic water-soluble medicine
INVENTOR(S): Satoh, Motoaki; Sakai, Yasuyuki; Shishikura, Takashi; Yokoi, Hirotsugu; Ishikura, Toyoaki; Sugimori, Hiroko; Ebisawa, Hisashi; Takahashi, Michiyo; Hasegawa, Yuko
PATENT ASSIGNEE(S): Showa Denko K. K. , Japan
SOURCE: Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 189861	A2	19860806	EP 1986-100939	19860124
EP 189861	A3	19880217		
R: CH, DE, FR, GB, IT, LI				
JP 61172830	A	19860804	JP 1985-11767	19850126
JP 61254532	A	19861112	JP 1985-93821	19850502
JP 61260026	A	19861118	JP 1985-100483	19850514
JP 61260027	A	19861118	JP 1985-100484	19850514
JP 61268631	A	19861128	JP 1985-108332	19850522
JP 61268632	A	19861128	JP 1985-109279	19850523
JP 62061929	A	19870318	JP 1985-201738	19850913

PRIORITY APPLN. INFO.:

JP 1985-11767	A	19850126
JP 1985-93821	A	19850502
JP 1985-100483	A	19850514
JP 1985-100484	A	19850514
JP 1985-108332	A	19850522
JP 1985-109279	A	19850523
JP 1985-201738	A	19850913

AB Percutaneous absorption of cationic or ionic water-soluble drugs is accelerated by incorporating ionic oil-soluble substances and their salts, amphoteric surfactants, and nonionic substances into transdermal prepns. Thus, diltiazem-HCl (I) 0.6 and dehydrocholic acid 0.1 g were added to a gel which was prepared from an aqueous solution containing polyvinyl alc. 0.6 and glycerol 0.6 g in 7 mL water. The gel was spread onto a polyethylene film

support, followed by heating to 50° for 15 h to give a dried transdermal film. The film was applied to shaved skin portions of rabbits. The concentration of I in the plasma was determined to be 0.092, 0.080, 0.077, 0.71, and 0.036 μg/mL at 1, 2, 4, 7, 24 h, resp., after its application. The comparative test with the film prepared in the same manner, except dehydrocholic acid was not used, showed 0.008, 0.013, 0.015, 0.011, and 0.005 μg/mL plasma, resp., at the same time interval.

IT 770-05-8
RL: BIOL (Biological study)
(transdermal formulation of, absorption accelerator for)

RN 770-05-8 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L8 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1983:403361 CAPLUS
DOCUMENT NUMBER: 99:3361
ORIGINAL REFERENCE NO.: 99:658h,659a
TITLE: The chromatic and motor effects of neurotransmitter injection in intact and brain-lesioned Octopus
AUTHOR(S): Andrews, P. L. R.; Messenger, J. B.; Tansey, E. M.
CORPORATE SOURCE: Med. Sch., Univ. Edinburgh, Edinburgh, EH8 9AG, UK
SOURCE: Journal of the Marine Biological Association of the United Kingdom (1983), 63(2), 355-70
CODEN: JMBAAK; ISSN: 0025-3154
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Various neurotransmitters were injected into the blood supplying the brain of O. vulgaris and the effects, particularly on the chromatophores, were observed L-Glutamate, GABA, dopamine, noradrenaline, and octopamine caused expansion of the chromatophores and darkening of the skin; acetylcholine (ACh) caused retraction of the chromatophores and paling; 5HT caused differential expansion and retraction (mottling). These responses, which are neurally mediated, were particularly well defined for ACh and 5HT. The paling effect of ACh was mimicked by nicotine but not muscarine and was partially antagonized by tubocurarine. The mottling induced by 5HT was transiently antagonized by methylsergide maleate, as was ink-ejection and defecation. Brain lesions to localize the sites of action of ACh and 5HT suggest that they act at the level of the subesophageal lobes to control the chromatophores, but that 5HT may act at the level of the optic lobe to control inking and defecation. These results are related to the pharmacol. and histochem. of the cephalopod brain and to the organization of the chromatophore control system.

IT 104-14-3
RL: BIOL (Biological study)
(chromatophores of octopus response to, nervous system mediation of)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1981:562597 CAPLUS
DOCUMENT NUMBER: 95:162597
ORIGINAL REFERENCE NO.: 95:27043a,27046a
TITLE: Color changes in cephalopods after neurotransmitter injection into the cephalic aorta
AUTHOR(S): Andrews, P. L. R.; Messenger, J. B.; Tansey, E. M.
CORPORATE SOURCE: Dep. Physiol., Univ. Edinburgh, Edinburgh, EH8 9AG, UK
SOURCE: Proceedings of the Royal Society of London, Series B: Biological Sciences (1981), 213(1190), 93-9, 1 plate
CODEN: PRLBA4; ISSN: 0080-4649
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A method by which small quantities (1-10 μg) of neurotransmitters can be injected into the blood supplying the brain of cephalopods (mainly Octopus vulgaris) was used to produce conspicuous and instantaneous color changes in the skin of the arms, head, and body. Of the transmitter substances known to be present in the cephalopod brain, dopamine [51-61-6], noradrenaline [51-41-2], and octopamine [104-14-3] caused darkening when injected, acetylcholine [51-84-3] caused paling and 5-HT [50-67-9] elicited a mottled patterning. Other evidence is presented that these substances are acting centrally to produce these effects, and the findings are related to the known organization of the lobes in the central nervous system controlling the chromatophores.
IT 104-14-3
RL: BIOL (Biological study)
(cephalopods chromatophore response to, after central administration)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L8 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1979:198090 CAPLUS
DOCUMENT NUMBER: 90:198090
ORIGINAL REFERENCE NO.: 90:31403a,31406a
TITLE: Adrenergic activity of ortho-, meta-, and para-octopamine
AUTHOR(S): Fregly, Melvin J.; Kelleher, D. L.; Williams, C. M.
CORPORATE SOURCE: Coll. Med., Univ. Florida, Gainesville, FL, USA

SOURCE: Pharmacology (1979), 18(4), 180-7
CODEN: PHMGBN; ISSN: 0031-7012
DOCUMENT TYPE: Journal
LANGUAGE: English
AB DL-O-octopamine [70080-69-2], DL-m-octopamine-HCl (I) [15308-34-6] and DL-p-octopamine-HCl [770-05-8], were tested for β- and α-adrenergic activity in rats. When compared to DL-isoproterenol, all 3 isomers failed to show significant β-adrenergic activity as assessed by initiation of thirst and by increase in tail skin temperature All 3 isomers increased mean blood pressure in pentolinium-blocked rats. Of the 3 isomers, I possessed the greatest α-adrenergic activity. The activities of m-, p-, and o-octopamine were 0.01, 0.0005, and 0.00007, resp., compared to the standard activity of 1 for norepinephrine.
IT 770-05-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(adrenergic activity of)
RN 770-05-8 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



L8 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:53836 CAPLUS
DOCUMENT NUMBER: 84:53836
ORIGINAL REFERENCE NO.: 84:8777a,8780a
TITLE: Effect of pharmacological agents on human keratinocyte mitosis in vitro. II. Inhibition by catechol amines
AUTHOR(S): Harper, Robert A.; Flaxman, B. Allen
CORPORATE SOURCE: Health Sci. Cent., Temple Univ., Philadelphia, PA, USA
SOURCE: Journal of Cellular Physiology (1975), 86(2, Pt. 1), 293-9
CODEN: JCLLAX; ISSN: 0021-9541
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Catechol amines produce mitotic inhibition in primary cell cultures of human keratinocytes probably via a block in the G2 part of the cell cycle. Epinephrine [51-43-4] produced mitotic inhibition (49%) at a concentration as low as 4.5 + 10-10M, while its analog, isoproterenol [7683-59-2], produced 47% inhibition at 1 + 10-10M. Norepinephrine [51-41-2] elicited a 49% inhibitory response at 1 + 10-8M. One other catechol amine, dopamine [51-61-6], caused a 53% decrease in mitosis at 1 + 10-6M. Other structurally related amines to exhibit mitotic inhibition were phenylephrine [59-42-7], 58% at 1 + 10-7M; octopamine [104-14-3], 47% at 1 + 10-5M; and tyramine [51-67-2], 52% at 1 + 10-4M. Serotonin [50-67-9] showed no mitotic inhibition at 1 + 10-4M. Various α- and β-adrenergic blocking agents

were added to the cell system. The α-blocking agent, phentolamine, had no effect on mitosis. When added in conjunction with epinephrine or norepinephrine, no reduction of the catechol amine-induced mitotic inhibition was observed The β-blocking agent, propranolol [525-66-6], by itself showed slight mitotic inhibition at 1 + 10-6M. When added along with epinephrine or norepinephrine, propranolol reduced the catechol amine-induced mitotic inhibition approx. 65%. In addition, propranolol blocked mitotic inhibition caused by phenylephrine [59-42-7], an α-adrenergic agent. However, another β-blocking agent, dichloroisoproterenol [59-61-0], showed strong mitotic inhibition (53%) when added alone to the cultures at a concentration of 1 + 10-8M. The effect was reduced to zero in the presence of propranolol. These data suggest that while β-receptors may be involved in the catechol amine-induced mitotic inhibition of human keratinocytes in vitro, the nature of the receptor-mol. interaction may be complex.

IT 104-14-3
RL: BIOL (Biological study)
(mitosis by skin inhibition by, receptors in relation to)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



```
=>
=> s L8 AND sunscreen
          6302 SUNSCREEN
         10825 SUNSCREENS
         11587 SUNSCREEN
                 (SUNSCREEN OR SUNSCREENS)
L9          12 L8 AND SUNSCREEN

=> d L9 1-12 ibib abs hitstr
```

L9 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:993749 CAPLUS

DOCUMENT NUMBER: 147:330433

TITLE: Composition and method for topical treatment of tar-responsive dermatological disorders

INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling

PATENT ASSIGNEE(S): Tristrata, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070207222	A1	20070906	US 2007-680227	20070228
AU 2007223560	A1	20070913	AU 2007-223560	20070228
AU 2007223560	A2	20081016		
CA 2644311	A1	20070913	CA 2007-2644311	20070228

WO 2007103687 A2 20070913 WO 2007-US62975 20070228
WO 2007103687 A3 20081211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1998788 A2 20081210 EP 2007-757636 20070228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.: US 2006-778128P P 20060301
WO 2007-US62975 W 20070228

AB The present invention relates to a composition including a wax and a therapeutically effective amount of tar for topical treatment of a tar-responsive dermatol. disorder, the composition being in liquid or light gel form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal. The invention also relates to a method of treating a tar-responsive dermatol. disorder by topically applying the composition to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liquid tar composition was formulated containing coal tar solution 15 g, ethanol 42 g, propylene glycol 5 g, cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liquid wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the composition for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

IT 104-14-3, Octopamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for topical treatment of tar-responsive dermatol. disorders)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L9 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:763639 CAPLUS
DOCUMENT NUMBER: 147:173626
TITLE: Pharmaceutical compositions containing N-(phosphonoalkyl)-amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 23pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070161543	A1	20070712	US 2007-621287	20070109
US 7429575	B2	20080930		
AU 2007204755	A1	20070719	AU 2007-204755	20070109
CA 2637027	A1	20070719	CA 2007-2637027	20070109
WO 2007082206	A2	20070719	WO 2007-US60273	20070109
WO 2007082206	A3	20071213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1979366	A2	20081015	EP 2007-717264	20070109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080306025	A1	20081211	US 2008-194203	20080819
CN 101395164	A	20090325	CN 2007-80007801	20080904

PRIORITY APPLN. INFO.:
US 2006-757614P P 20060110
US 2007-621287 A3 20070109
WO 2007-US60273 W 20070109

OTHER SOURCE(S): MARPAT 147:173626

AB The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)glycine or N,N-bis(phosphonomethyl)glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system. N-(phosphonomethyl)creatinine and propylene glycol were used in the preparation of a topical composition

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing N-(phosphonoalkyl)-amino acids)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:146724 CAPLUS
DOCUMENT NUMBER: 146:235482
TITLE: Topical deodorant compositions based on hydroxycitric acid
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): Bioderm Research, USA
SOURCE: U.S. Pat. Appl. Publ., 6pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070031526	A1	20070208	US 2005-161511	20050805
PRIORITY APPLN. INFO.:			US 2005-161511	20050805

AB This invention relates to the use of hydroxycitric acid and its derivs. in cosmetic and pharmaceutical compns. for reducing body malodor. Thus, a composition contained stearalkonium bentonite 0.5, aluminum chlorohydrate 7.0, niacinamide hydroxystearate 1.0, C12-15 alkyl benzoate 3.0, cyclopentasiloxane 6.5, tri-Et citrate 1.0, iso-Pr palmitate 1.0, and isobutane 80.0%.

IT 923587-25-1
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(topical deodorant compns. based on hydroxycitric acid)
RN 923587-25-1 CAPLUS
CN D-erythro-Pentaric acid, 3-C-carboxy-2-deoxy-, compd. with α-(aminomethyl)-4-hydroxybenzenemethanol (1:?) (CA INDEX NAME)

CM 1

CRN 27750-10-3
CMF C6 H8 O8

Absolute stereochemistry. Rotation (-).



CM 2

CRN 104-14-3

CMF C8 H11 N O2



L9 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:681023 CAPLUS
DOCUMENT NUMBER: 145:174286
TITLE: Pharmaceutical compositions comprising o-acetylsalicyl derivatives of amino saccharides and amino acids
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074114	A2	20060713	WO 2005-US47669	20060103
WO 2006074114	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20060166901	A1	20060727	US 2005-320530	20051229
AU 2006204136	A1	20060713	AU 2006-204136	20060103
CA 2593055	A1	20060713	CA 2006-2593055	20060103
EP 1843661	A2	20071017	EP 2005-856124	20060103
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008526774	T	20080724	JP 2007-549694	20060103
CN 101128117	A	20080220	CN 2005-80048674	20070824

PRIORITY APPLN. INFO.:

US 2005-640225P	P	20050103
US 2005-320530	A	20051229
WO 2005-US47669	W	20060103

AB The embodiments described herein include a composition and method of treatment using compns. that include at least 1 acetylsalicyl derivative The compns. and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems. N-(O-acetylsalicyl)-D-galactosamine 5 g was dissolved in warm propylene glycol 35 mL, and the solution thus obtained was mixed with hydrophilic ointment or oil-in-water cream (60 g). The cream thus prepared had pH 3.9 and contained 5% N-(O-acetylsalicyl)-D-galactosamine.

IT 104-14-3, Octopamine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising acetylsalicyl derivs. of amino saccharides and amino acids)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L9 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:491792 CAPLUS
DOCUMENT NUMBER: 145:14124
TITLE: Topical delivery system comprising esters of hydroxy acids for cosmetic and pharmaceutical agents
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): Bioderm Research, USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060110415	A1	20060525	US 2004-904665	20041122
US 20070166255	A1	20070719	US 2007-670942	20070202
PRIORITY APPLN. INFO.:			US 2004-904665 A2	20041122
			US 2005-161856 A2	20050819

AB This invention relates to topical compns. containing esters of hydroxy acids and their application in the deep-penetration delivery of beneficial cosmetic and pharmaceutical agents. An ester of a hydroxy acid is selected from alkyl and aryl esters of glycolic, malic, lactic, mandelic, ascorbic, phytic, salicylic, aleuritic, and tartaric acids, etc. Thus, a skin whitening serum was prepared containing Et lactate 20.0, hydroxypropyl guar 0.5,, quinacetophenone 5.0, PEG-6 70.0, arbutin 4.0, and preservatives 0.5 parts, resp. The product had a clear to slightly hazy serum-like appearance. It was absorbed rapidly with a silky smooth skin feel. Also, an arthritis pain relief anti-inflammatory gel was prepared containing tri-Et citrate 55.65, Polyamide-3 5.0, preservative 0.5,
Boswellia serrata extract 0.05, N-acetylglucosamine 2.0, methylsulfonylmethane 5.0, Aloe vera 0.1, vitamin E 0.5, paeonol 0.5, magnolol 0.2, chondroitin sulfate 0.5, and zeolite 30.0 parts, resp.
IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical delivery systems comprising esters of hydroxy acids as penetration enhancers for cosmetic and pharmaceutical uses)
RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L9 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:877940 CAPLUS
DOCUMENT NUMBER: 141:370229
TITLE: Controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040208902	A1	20041021	US 2003-418495	20030418
US 20060127430	A1	20060615	US 2006-307824	20060224
US 20070166339	A1	20070719	US 2007-684702	20070312
US 20070237834	A1	20071011	US 2007-760466	20070608
PRIORITY APPLN. INFO.:			US 2003-418495 A2	20030418
			US 2003-605191 A2	20030914
			US 2004-710011 A2	20040611
			US 2006-307824 A2	20060224

AB The present invention discloses the utilization of zeolites for controlled-release of cosmetic and pharmaceutical compns. by nano-diffusion technol. The treatment and protection of skin surface requires that certain compns. be delivered to the skin surface and allowed to remain on the skin surface for as long as possible before such ingredients are absorbed into deeper layers of skin and carried into the bloodstream. Zeolites do not absorb into the skin, which is useful for topical delivery of cosmetic and pharmaceutical compns., for example antiaging, anti-wrinkle, antioxidants, skin whitening, acne treatment, rosacea treatment, sun screens, UV blocks, anesthetics, skin soothers, anti-irritants, anti-inflammatory agents, vitamins, hormones, and such that are electronically attached to the outer surfaces of such zeolites and are released to the outer surface of skin by a diffusion-controlled thermodn. process. An anhydrous face mask controlled-release antiaging composition with heat-releasing effect. comprises magnesium sulfate (anhydrous) 30.0, glycerin 49.0, sodium potassium aluminosilicate (Zeolite A3) 20.0, an antiaging composition (an equal weight mixture of tetrahydrocurcumin, niacinamide lactate, copper ATP complex, glutathione, and carnosine)1.0%.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release nano-diffusion delivery systems for cosmetic and pharmaceutical compns.)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L9 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:780544 CAPLUS
DOCUMENT NUMBER: 141:301421
TITLE: Improved bioavailability and improved delivery of alkaline drugs
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080468	A1	20040923	WO 2004-US6699	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040214215	A1	20041028	US 2004-792273	20040304
AU 2004220597	A1	20040923	AU 2004-220597	20040305
CA 2517782	A1	20040923	CA 2004-2517782	20040305
EP 1601366	A1	20051207	EP 2004-717955	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:
US 2003-452557P P 20030307
US 2004-792273 A 20040304
WO 2004-US6699 A 20040305

OTHER SOURCE(S): MARPAT 141:301421

AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition The compns. include a mol. complex formed between an alkaline pharmaceutical and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, diphenhydramine hydrochloride 29 g (0.1 mol) was dissolved in water (50 mL) and 5N sodium hydroxide (20 mL) was slowly added to generate diphenhydramine as a free base as shown by the formation of oily ppts. and the change from pH 5.5 to 9.4. Gluconolactone 18 g (0.1 mol) was added to form a mol. complex between the diphenhydramine free base and gluconic acid/gluconolactone as shown by the disappearance of the oily ppts. and the change from pH 9.4 to 7.4. The solution thus obtained contained 0.1 mol

diphenhydramine in mol. complex with 0.1 mol gluconic acid/gluconolactone. This concentrated stock solution was used for various forms of topical formulations including oil-in-water creams, lotions, gels and solns.

IT 104-14-3, Octopamine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved bioavailability and improved delivery of alkaline drugs using hydroxy acids)

RN 104-14-3 CAPLUS
CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:780130 CAPLUS
DOCUMENT NUMBER: 141:282441
TITLE: Hydroxycitric acid derivatives for body slimming and tone firming compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 17
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040185069	A1	20040923	US 2003-394851	20030322
US 20060147508	A1	20060706	US 2006-307729	20060218

PRIORITY APPLN. INFO.:

US 2002-265000	A2	20021004
US 2002-280519	A2	20021025
US 2002-290933	A2	20021107
US 2003-394851	A2	20030322
US 2003-439349	A2	20030515

AB The present invention discloses cosmetic or topical pharmaceutical compns. for body slimming, firming, cellulite reduction, fat-reduction, and obesity control benefits that can be selective and specific for external body parts and organs such as face, chin, cheeks, arms, "love handles" in abdomen area, eye lids and eye zone, neck, breasts, thighs, and hips. These compns. include a synergistic, bioavailability-enhanced ion-pair combination of Hydroxycitric acid or Hydroxycitric acid derivs. with certain organic bases such as Niacinamide, Niacin, Pyridoxine, Aminophylline, Caffeine, Carnitine, Creatine, Chitosan, Allantoin, Glucosamine, Phaseolamine, Chromium Picolinate, Theobromine, Theophylline, and such.

IT 757237-79-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxycitric acid derivs. for body slimming and tone firming compns.)

RN 757237-79-9 CAPLUS
CN Pentaric acid, 3-C-carboxy-2-deoxy-, compd. with

α-(aminomethyl)-4-hydroxybenzenemethanol (9CI) (CA INDEX NAME)

CM 1

CRN 6205-14-7
CMF C6 H8 O8



CM 2

CRN 104-14-3
CMF C8 H11 N O2



L9 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:681187 CAPLUS
DOCUMENT NUMBER: 141:194959
TITLE: Skin firming anti-aging cosmetic compositions
INVENTOR(S): Gupta, Shyam K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040161435	A1	20040819	US 2003-248753	20030214

PRIORITY APPLN. INFO.: US 2003-248753 20030214

AB Cosmetic mask compns. suitable for face, neck, chin or body applications are disclosed. These compns. synergistically combine at least 1 skin beneficial cosmetic or pharmaceutical composition with at least one composition to promote excess fat reduction, cellulite control, or muscle toning benefits. The mask composition also contains at least one binder composition that binds with other beneficial ingredients by electrostatic, atomic, or ionic charges to synergistically enhance their topical site-specific benefits. These mask compns. are suitable for a variety of delivery system methods that include, e.g., peel-off mask, leave-in mask, moisturizing mask, and exfoliating mask. Thua, a facial mask composition contained chitosan 5.0, lactic acid 5.0, glycerin 18.0, water 65.8, hydroxycitric acid 5.0, niacinamide 0.5, glutathione, and preservatives

0.5%.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(skin firming anti-aging cosmetic compns.)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L9 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:609740 CAPLUS

DOCUMENT NUMBER: 141:162091

TITLE: Topical nutraceutical compositions with selective body slimming and tone firming antiaging benefits

INVENTOR(S): Gupta, Shyam K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040146539	A1	20040729	US 2003-248508	20030124

PRIORITY APPLN. INFO.: US 2003-248508 20030124

AB Cosmetic or topical pharmaceutical compns. are described for external body part or organ slimming, firming, cellulite reduction, fat-reduction, and obesity control benefits that are in synergistic combination with benefits for the treatment of skin aging, skin wrinkles reduction, skin exfoliating, treatment of acne, treatment of rosacea, age-spots reduction, skin surface whitening, skin surface brightening striae distensae (stretch marks) reduction, treatment of pimples, treatment of skin infections and lesions, spider veins reduction, blood microcirculation (venous insufficiency) improvement, UVA/UVB protection of skin, and skin redness reduction These compns. thus provide multiple combinations of skin and external body part or organ enhancement benefits that can be selective and specific for external body parts and organs such as face, chin, cheeks, arms, "love handles" in abdomen area, eye lids and eye zone, neck, breasts, thighs, and hips. For example, a chitosan facial mask composition for the reduction of wrinkles and excess fat on cheeks and eyelids contained chitosan 5%, lactic acid 5%, glycerin 18%, water 65.8%, hydroxycitric acid 5%, niacinamide 0.5%, glutathione 0.2%, and preservatives 0.5%. First three components were mixed into a paste, other components were mixed sep. into a clear solution, and the paste and the solution were combined to obtain a clear gel product. The gel is applied on the face and neck and left for 10 to 30 min, then rinsed off.

IT 104-14-3, Octopamine
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(topical nutraceutical compns. with selective body slimming and tone firming antiaging benefits)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



L9 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:20643 CAPLUS

DOCUMENT NUMBER: 140:77297

TITLE: Method for preparing cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and use thereof

INVENTOR(S): Lintner, Karl

PATENT ASSIGNEE(S): Sederma, Fr.

SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002941	A1	20040108	WO 2003-FR1950	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2841550	A1	20040102	FR 2002-7965	20020626
FR 2841550	B1	20070504		
AU 2003253080	A1	20040119	AU 2003-253080	20030625
EP 1532102	A1	20050525	EP 2003-761635	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060110343	A1	20060525	US 2005-519118	20050929
JP 2007106697	A	20070426	JP 2005-299255	20051013
KR 2007041310	A	20070418	KR 2006-71964	20060731
CN 101182299	A	20080521	CN 2007-10129837	20070727

PRIORITY APPLN. INFO.:			
FR 2002-7965	A	20020626	
WO 2003-FR1950	W	20030625	
JP 2005-299255	A	20051013	
KR 2006-71964	A	20060731	

OTHER SOURCE(S): CASREACT 140:77297; MARPAT 140:77297

GI



I

AB The invention concerns cosmetic or dermopharmaceutical compns. comprising tyramine derivs. I [X = NR3R4, N:CR5R6; R1, R2 = H, halogen, alkyl, aryl, aralkyl, acyl, OH, alkoxy; R3, R4 = H, alkyl, aryl, aralkyl, acyl, sulfonyl, sugar; R5, R6 = H, alkyl, aryl, aralkyl; with the exception of tyramine itself, its OH derivs., its NH2 acyl derivs. {(un)branched, (un)saturated C1-24-acyl, C1-24-hydroxyacyl, C1-24-mercaptoacyl} and synephrine (I; X = NHMe, R1 = OH, R2 = H)], their optical isomers, isomeric mixts. and their cosmetically acceptable salts. Thus, N,N'-bis(tyramine)urea [I; X=NC(:O)NH(CH2)2C6H4OH-4 (II)] was prepared from tyramine hydrochloride and carbonyl diimidazole in THF containing K2CO3. The invention also concerns the method for preparing same and use thereof for reducing pigmentation. A formulation for a depigmentation cream using II is described.

IT 104-14-3DP, Octopamine, and salts
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for preparing cosmetic or dermopharmaceutical compns. comprising tyramine derivs. and use thereof)

RN 104-14-3 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:555966 CAPLUS
DOCUMENT NUMBER: 109:155966
ORIGINAL REFERENCE NO.: 109:25825a,25828a
TITLE: Sunscreens containing N-(hydroxystyryl)benzamide
INVENTOR(S): Fujii, Seishiro; Nishitani, Hiroshi; Kitamura, Kanemoto; Ishiwatari, Katsumi
PATENT ASSIGNEE(S): Shiseido Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62283912	A	19871209	JP 1986-127043	19860531

PRIORITY APPLN. INFO.: JP 1986-127043 19860531

GI



I

AB A sunscreen composition comprises N-(hydroxystyryl)benzamide (I) as a UV absorber. I absorbs wavelength 290-320 nm of sun rays and prevents inflammations. Octopamine-HCl dissolved in pyridine was reacted with benzoyl chloride to give N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide, which was refluxed in toluene in the presence of Al2O3 to give cis- and trans-N-(4-hydroxystyryl)benzamide. The above compds. had no skin -irritating side effects and no phototoxicity. A sunscreen cream contained water 41.0, polyethylene glycol 5.0, a dispersing agent q.s., cetyl alc. 5.0, vaseline 10.0, olive oil 15.0, liquid paraffin 5.0, microcryst. wax 5.0, glyceryl monostearate 2.0, polyoxyethylene sorbitan monostearate 2.0, N-(4-hydroxystyryl)benzamide 5.0% by weight, perfume q.s., preservative q.s., antioxidant q.s., TiO2 5.0% by weight, and color q.s.

IT 770-05-8, Octopamine hydrochloride
RL: BIOL (Biological study)
(condensation of, with benzoyl chloride)

RN 770-05-8 CAPLUS

CN Benzenemethanol, α-(aminomethyl)-4-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	314.42	388.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-39.36	-39.36

STN INTERNATIONAL LOGOFF AT 06:54:29 ON 29 APR 2009